Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1986235
PUBLISHER: BCC Research | PRODUCT CODE: 1986235
Global Bispecific Antibodies Market
PUBLISHED:
PAGES: 127 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report provides an overview of the global bispecific antibodies market and analyzes market trends. It includes global revenue ($ million) for the base year data for 2022- 2024 and estimated data for the forecast period from 2025 through 2030.
Report Scope
The report provides an overview of the global market for bispecific antibodies. It includes global revenue ($ million) for the base year of 2024, estimated revenue for 2025, and data for the forecast period 2026 through the end of 2030. The report also analyzes and segments the global bispecific antibodies market by route of administration, mechanisms of action, application, and end user. It also provides insights into key emerging trends and potential growth drivers. The study focuses on the route of administration, including intravenous (IV), subcutaneous (SC), and other. The market is segmented by application into cancer treatment, autoimmune disorders, and other. By mechanism of action, the market focuses on T-cell redirecting bispecific antibodies, dual-antigen tumor-targeting bispecific antibodies, and other. The market is segmented by end users as pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions.
The report provides a comprehensive regional analysis covering North America, Europe, Asia-Pacific, South America, the Middle East, and Africa. It evaluates market dynamics, including drivers, challenges, and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major companies and their offerings.
Report Includes
- Analysis of the global market for bispecific antibodies (bsAbs), a novel approach to anticancer therapy
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by route of administration, mechanisms of action, application, end user, and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading global companies
Product Code: PHM290A
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Future Outlook
- Macroeconomic Factors Analysis
- Demographic Factors
- Global Economic Growth
- Impact of U.S. Tariffs
- Impact of the Ukraine-Russia War on the Bispecific Antibodies Industry
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Threat of Substitutes
- Competitiveness in the Industry
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Rising Global Burden of Cancer
- R&D Investment by Large Pharmaceutical and Biotechnology Companies
- Growing Adoption of Immuno-Oncology Therapies in Standard Treatment Pathways
- Market Restraints
- High Treatment Cost and Pricing Pressure
- Shortage of Oncology Professionals
- Stringent Government Regulations
- Market Opportunities
- Development of Bispecific Antibodies for Solid Tumors
- Expansion in Emerging Markets
Chapter 4 Regulatory Landscape
- Overview
- U.S.
- Europe
- Asia-Pacific
Chapter 5 Emerging Technologies
- Overview
- Newest Technologies/Trends
- Next-Generation Bispecific Antibody Formats with Improved Stability and Half-Life
- Subcutaneous and Outpatient Administration Optimized Bispecific Antibodies
- AI-Assisted Antibody Design and Target Selection
- Combination Regimens with Immune Checkpoint Inhibitors or Targeted Therapies
- Conditional Activation and Tumor-Restricted Bispecific Designs
Chapter 6 Market Segment Analysis
- Segmentation Breakdown
- Global Bispecific Antibodies Market, by Route of Administration
- Key Takeaways
- Intravenous (IV)
- Subcutaneous (SC)
- Others
- Global Bispecific Antibodies Market, by Application
- Key Takeaways
- Cancer Treatment
- Autoimmune Disorders
- Others
- Global Bispecific Antibodies Market, by Mechanisms of Action
- Key Takeaways
- T-cell Redirecting Bispecific Antibodies
- Dual-Antigen Tumor-targeting Bispecific Antibodies
- Others
- Global Bispecific Antibodies Market, by End User
- Key Takeaways
- Pharmaceutical and Biotechnology Companies
- CROs
- Academic and Research Institutions
- Geographic Breakdown
- Global Bispecific Antibodies Market, by Region
- Key Takeaways
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Chapter 7 Clinical Trial and Patent Analyses
- Clinical Trial Analysis
- Key Takeaway
- Patent Analysis
- Key Takeaways
- Patents, by Jurisdiction
- Patents, by Applicants
Chapter 8 Competitive Intelligence
- Key Takeaways
- Strategic Analysis
Chapter 9 Appendix
- Research Methodology
- Sources
- Acronyms
- Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- JAZZ PHARMACEUTICALS INC.
- JOHNSON & JOHNSON
- LILLY USA LLC.
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- Emerging Start-ups/ Market Disruptors
Product Code: PHM290A
List of Tables
- Summary Table : Global Market for Bispecific Antibodies, by Region, Through 2030
- Table 1 : Current Health Expenditure, by Select Countries/Regions, 2021-2023
- Table 2 : Global Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 3 : Global Market for Intravenous (IV) Route of Administration, by Region, Through 2030
- Table 4 : Global Market for Subcutaneous (SC) Route of Administration, by Region, Through 2030
- Table 5 : Global Market for Other Route of Administration, by Region, Through 2030
- Table 6 : Global Market for Bispecific Antibodies, by Application, Through 2030
- Table 7 : Global Market for Cancer Treatment, by Region, Through 2030
- Table 8 : Global Market for Autoimmune Disorder Treatments, by Region, Through 2030
- Table 9 : Global Market for Other Applications, by Region, Through 2030
- Table 10 : Global Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 11 : Global Market for T-cell Redirecting Bispecific Antibodies, by Region, Through 2030
- Table 12 : Global Market for Dual-Antigen Tumor-targeting Bispecific Antibodies, by Region, Through 2030
- Table 13 : Global Market for Other Mechanisms of Action, by Region, Through 2030
- Table 14 : Global Market for Bispecific Antibodies Market, by End User, Through 2030
- Table 15 : Global Market for Pharmaceutical and Biotechnology Companies, by Region, Through 2030
- Table 16 : Global Market for Contract Research Organizations (CROs), by Region, Through 2030
- Table 17 : Global Market for Academic and Research Institutions, by Region, Through 2030
- Table 18 : Global Market for Bispecific Antibodies, by Region, Through 2030
- Table 19 : North American Market for Bispecific Antibodies, by Country, Through 2030
- Table 20 : North American Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 21 : North American Market for Bispecific Antibodies, by Application, Through 2030
- Table 22 : North American Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 23 : North American Market for Bispecific Antibodies, by End User, Through 2030
- Table 24 : European Market for Bispecific Antibodies, by Country, Through 2030
- Table 25 : European Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 26 : European Market for Bispecific Antibodies, by Application, Through 2030
- Table 27 : European Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 28 : European Market for Bispecific Antibodies, by End User, Through 2030
- Table 29 : Asia-Pacific Market for Bispecific Antibodies, by Country, Through 2030
- Table 30 : Asia-Pacific Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 31 : Asia-Pacific Market for Bispecific Antibodies, by Application, Through 2030
- Table 32 : Asia-Pacific Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 33 : Asia-Pacific Market for Bispecific Antibodies, by End User, Through 2030
- Table 34 : MEA Market for Bispecific Antibodies, by Sub-Region, Through 2030
- Table 35 : MEA Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 36 : MEA Market for Bispecific Antibodies, by Application, Through 2030
- Table 37 : MEA Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 38 : MEA Market for Bispecific Antibodies, by End User, Through 2030
- Table 39 : South American Market for Bispecific Antibodies, by Country, Through 2030
- Table 40 : South American Market for Bispecific Antibodies, by Route of Administration, Through 2030
- Table 41 : South American Market for Bispecific Antibodies, by Application, Through 2030
- Table 42 : South American Market for Bispecific Antibodies, by Mechanism of Action, Through 2030
- Table 43 : South American Market for Bispecific Antibodies, by End User, Through 2030
- Table 44 : Selected Bispecific Antibodies Clinical Trials Studies, 2025
- Table 45 : Patents Granted for Bispecific Antibodies, by Applicants, January 2022-December 2025
- Table 46 : Strategic Initiatives in the Global Bispecific Antibodies Market, 2025
- Table 47 : Information Sources in This Report
- Table 48 : Abbreviations Used in the Global Bispecific Antibodies Market
- Table 49 : AbbVie Inc.: Company Snapshot
- Table 50 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
- Table 51 : AbbVie Inc.: Product Portfolio
- Table 52 : AbbVie Inc.: News/Key Developments, 2023-2025
- Table 53 : Amgen Inc.: Company Snapshot
- Table 54 : Amgen Inc.: Financial Performance, FY 2023 and 2024
- Table 55 : Amgen Inc.: Product Portfolio
- Table 56 : Amgen Inc.: News/Key Developments, 2025
- Table 57 : AstraZeneca: Company Snapshot
- Table 58 : AstraZeneca: Financial Performance, FY 2023 and 2024
- Table 59 : AstraZeneca: Product Portfolio
- Table 60 : AstraZeneca: News/Recent Developments, 2022-2023
- Table 61 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 62 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
- Table 63 : Bristol-Myers Squibb Co.: Product Portfolio
- Table 64 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
- Table 65 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 66 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
- Table 67 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 68 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
- Table 69 : Jazz Pharmaceuticals Inc.: Company Snapshot
- Table 70 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
- Table 71 : Jazz Pharmaceuticals Inc.: Product Portfolio
- Table 72 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2024-2025
- Table 73 : Johnson & Johnson: Company Snapshot
- Table 74 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
- Table 75 : Johnson & Johnson: Product Portfolio
- Table 76 : Johnson & Johnson: News/Key Developments, 2022-2025
- Table 77 : Lilly USA LLC.: Company Snapshot
- Table 78 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
- Table 79 : Lilly USA LLC.: Product Portfolio
- Table 80 : Pfizer Inc.: Company Snapshot
- Table 81 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
- Table 82 : Pfizer Inc.: Product Portfolio
- Table 83 : Pfizer Inc.: News/Key Developments, 2023-2025
- Table 84 : Regeneron Pharmaceuticals Inc.: Company Snapshot
- Table 85 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
- Table 86 : Regeneron Pharmaceuticals Inc.: Product Portfolio
- Table 87 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2024-2025
- Table 88 : List of a Few Emerging Startups
List of Figures
- Summary Figure : Global Market Shares of Bispecific Antibodies, by Region, 2024
- Figure 1 : Porter's Five Forces Analysis of the Bispecific Antibodies Market
- Figure 2 : Bispecific Antibodies Market Dynamics
- Figure 3 : Estimated New Cancer Cases and Deaths in the U.S., 2024
- Figure 4 : Company R&D Expenditure Shares, by Function, 2022
- Figure 5 : Global Market Shares of Bispecific Antibodies, by Route of Administration, 2024
- Figure 6 : Global Market Shares of Bispecific Antibodies, by Application, 2024
- Figure 7 : Global Market Shares of Bispecific Antibodies Market, by Mechanisms of Action, 2024
- Figure 8 : Global Market Shares of Bispecific Antibodies Market, by End User, 2024
- Figure 9 : Global Market Shares of Bispecific Antibodies, by Region, 2024
- Figure 10 : North American Market Shares of Bispecific Antibodies, by Country, 2024
- Figure 11 : European Market Shares of Bispecific Antibodies, by Country, 2024
- Figure 12 : Asia-Pacific Market Shares of Bispecific Antibodies, by Country, 2024
- Figure 13 : MEA Market Shares of Bispecific Antibodies, by Sub-Region, 2024
- Figure 14 : South American Market Shares of Bispecific Antibodies, by Country, 2024
- Figure 15 : Patents Granted for Bispecific Antibodies, by Year, January 2022-December 2025
- Figure 16 : Patents Granted for Bispecific Antibodies, by Jurisdiction, January 2022-December 2025
- Figure 17 : Global Market Shares of the Bispecific Antibodies Industry, by Companies, 2024
- Figure 18 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 19 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 20 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 21 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 22 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
- Figure 23 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
- Figure 24 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
- Figure 25 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
- Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
- Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
- Figure 28 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 29 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 30 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
- Figure 31 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
- Figure 32 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
- Figure 33 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
- Figure 34 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 35 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 36 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.